CryoLife's CryoValve SG
This article was originally published in The Gray Sheet
Processed human aortic heart valve gains FDA humanitarian use device designation - the first step towards a humanitarian device exemption for replacing diseased, damaged, malformed or malfunctioning native or prosthetic aortic valves in children up to age 21. The firm's SynerGraft technology is used to remove allogeneic donor cells and cellular remnants from the valve without compromising the integrity of the underlying collagen matrix, CryoLife says
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.